Navigating The Journey from Bench to Bedside

Therapeutic antibodies continue to change how we treat human diseases. But antibody discovery and optimization present several challenges and the overwhelming majority of leads that enter pre-clinical testing will fail to navigate the twists and turns on the path to market. Even highly potent and specific candidates can have suboptimal developability profiles and face downstream aggregation, stability, formulation, or manufacturing problems.

Using our best-in-class discovery platform, Twist Biopharma’s antibody experts have discovered and vetted an array of lead antibodies against high-value targets, saving you the trouble of launching your own discovery projects and dealing with these problems internally. These fully human, IgG leads are engineered for developability, de-risked for common downstream liabilities, and built on a partnership aimed at accelerating your journey from bench to bedside.

Best-in-Class Therapeutics Start With a Best-in-Class Discovery Platform

Our unique, high-quality DNA writing platform allows us to design diverse antibody variants, with base-by-base precision. Using that as our foundation, we’ve built a best-in-class discovery platform, which served as the starting point for the antibody leads above. Each discovery project was led by our internal team of experts, with over 50 years of combined experience in therapeutic antibody development.

Enrich Your Pipeline With Antibodies Discovered and Vetted by Our Experts

Our library of libraries and internal expertise has enabled the discovery and selection of leads against challenging drug targets, like GLP-1R and ADORA2A. Once selected, each lead goes through our IgG conversion, expression, and purification and our high-throughput developability workflow to assess downstream pre-clinical success.